Immunitybio announces promising clinical study results for ‘kick and kill' hiv cure strategy to reduce hiv viral load with anktiva (n-803) therapy

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced promising study results that demonstrate the activation of cd4+ and cd8+ t cells and natural killer (nk) cells in people living with hiv by immunitybio's il-15 superagonist anktiva (n-803). anktiva stimulates latent hiv replication (the “kick”) in cd4 memory cells allowing the previously hidden infected cells to be revealed and eliminated (the “kill”) by cd8 and nk cel
IBRX Ratings Summary
IBRX Quant Ranking